Boehringer dual-acting obesity shot hits mark in Phase 3 trial

Boehringer dual-acting obesity shot hits mark in Phase 3 trial

Summary

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.

Description

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage